In this regard, targeted modulation of GSK-3α may hold promise as a viable strategy to improve NK cell reactivity against leukemia cells in addition to its direct anti-leukemic effects, given the upregulation of NKG2DL and NKp30L in leukemia cells upon GSK-3α inhibition. This evidence concerns the gene GSK3A and leukemia.